2. Metabolic Enzyme/Protease PI3K/Akt/mTOR Protein Tyrosine Kinase/RTK
  3. Farnesyl Transferase mTOR VEGFR
  4. Darlifarnib

Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment.

Para uso exclusivo en investigación. No vendemos a pacientes.

Darlifarnib

Darlifarnib Estructura química

No. CAS : 3065226-39-0

Tamaño Precio Stock Cantidad
500 μg Obtener un presupuesto 18 - 20 weeks 17 - 19 weeks 19 - 21 weeks 17 - 19 weeks
1 mg Obtener un presupuesto 18 - 20 weeks 17 - 19 weeks 19 - 21 weeks 17 - 19 weeks
5 mg Obtener un presupuesto 18 - 20 weeks 17 - 19 weeks 19 - 21 weeks 17 - 19 weeks
10 mg   Obtener un presupuesto  
50 mg   Obtener un presupuesto  
Synthetic products have potential research and development risk.

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 publication(s) in Google Scholar

Darlifarnib Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Darlifarnib

Ver todos los productos específicos de isoformas mTOR:

Ver todas las isoformas
mTOR mTORC1 mTORC2

Ver todos los productos específicos de isoformas VEGFR:

Ver todas las isoformas
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment[1].

IC50 & Target[1]

mTORC1

 

In Vitro

Darlifarnib (5-500 nM; 7 days) enhances the antiproliferative activity of anti-VEGFR TKIs in primary umbilical vein endothelial cells[1].
Combination treatment with darlifarnib (250 nM; 96 h) and an anti-VEGFR TKI (Axitinib (HY-10065), Lenvatinib (HY-10981), or Cabozantinib (HY-13016)) induces significantly higher levels of apoptosis in HUVEC cells compared to treatment with either agent alone[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Darlifarnib Related Antibodies
In Vivo

Darlifarnib (10 mg/kg; p.o.; twice daily; for 42 consecutive days) as a single agent induces tumor stasis, and in combination with anti-VEGFR TKIs, achieves durable tumor regression in Caki1 renal cell carcinoma xenografts[1].
Darlifarnib (20 mg/kg for KI-12-0073; p.o.; twice daily; 28-31 days) enhances cabozantinib-mediated tumor growth inhibition, induces tumor cell cycle arrest in multiple renal cell carcinoma xenograft models, and the combination treatment significantly reduces tumor angiogenesis and achieves durable tumor regression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice[1]
Dosage: 10 mg/kg
Administration: p.o.; twice daily; 42 days
Result: Induced tumor stasis, with mean percent tumor volume change near 0% at day 42.
Drove durable tumor regressions when combined with axitinib, lenvatinib, or cabozantinib, with mean percent tumor volume changes reaching negative values (tumor shrinkage) at day 42.
Animal Model: BALB/c nude mice; NOD/SCID mice (for KI-12-0097 PDX)[1]
Dosage: 20 mg/kg (KI-12-0073 PDX)
Administration: p.o.; twice daily; 28-31 days
Result: Enhanced tumor growth inhibition across all tested models when combined with Cabozantinib, inducing tumor regressions in 4 out of 6 models.
Led to more rapid and durable tumor regression than cabozantinib in the KI-12-0073 PDX model.
Significantly reduced CD31-positive endothelial area and NG2-positive pericyte area compared to cabozantinib in KI-12-0073 tumors after 14 days of treatment.
Peso molecular

468.51

Fòrmula

C29H20N6O
No. CAS
SMILES

N#CC1=CC(C2=CC(OCC3=CC([C@@]4(C5=CN=CN5C)N)=CC=C3C#N)=CC=C2)=C6C=C4C=CC6=N1
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Darlifarnib Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Darlifarnib3065226-39-0KO-2806KO2806KO 2806Farnesyl TransferasemTORVEGFRFtaseMammalian target of RapamycinVascular endothelial growth factor receptortyrosine kinase inhibitorsRHEBprimary human umbilical vein endothelial cellsanti-VEGFR TKIsCaki1 renal cell carcinoma xenograftsapoptosismTORC1endothelial cellscell cycle arrestrenal cell carcinomaInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Darlifarnib
Cat. No.:
HY-172423
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.